A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

Condition:   HIV-1 Infection Interventions:   Drug: ART;   Drug: DOR/ISL Sponsor:   Merck Sharp & Dohme LLC Not yet recruiting

Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials